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Satu kajian keratin rentas telah dilakukan untuk menilai kesesuaian rawatan anemia 
kekurangan besi semasa dan selepas kehamilan dengan menggunakan suntikan vena 
iron sucrose complex (Venofer) secara pesakit luar. Seramai 120 pesakit  dari Klinik 
Rawatan Harian Obstetrik, Hospital Universiti Kebangsaan Malaysia telah dikaji se-
lama 18 bulan, diantara March 2003 hingga Ogos 2004. Hasil ukuran utama ialah ke-
naikan aras hemoglobin, pematuhan pesakit, kesan sampingan dan kejimatan dari 
yuran masuk wad. Sebelum menerima rawatan, aras hemoglobin ibu mengandung 
ialah 8.5+0.85g/dl dan 7.6+0.80 g/dl bagi ibu selepas bersalin. Min kenaikan aras he-
moglobin selepas 14 hari merima rawatan ialah 3.52g/dl (2.9- 4.6g/dl). Hasil kajian 
menunjukkan seorang pesakit mengalami ruam kulit, dan seorang lagi mengalami de-
mam panas ringan. Tujuh orang pesakit mengalami rasa metalik. Tiada kesan buruk 
yang serius atau reaksi anafilaktik berlaku. Sepuluh pesakit (8.3%) tidak meyempurna-
kan terapi – lapan orang ibu bersalin sebelum pelengkapan rawatan, dan dua orang 
ibu gagal menghadiri diri selepas bersalin. Secara purata, setiap orang pesakit meng-
gunakan tujuh ampul Venofer iaitu 700mg, dan menjalani tempoh rawatan selama tiga 
hari. Rawatan sebagai pesakit luar mengelakkan dari tinggal di wad selama tiga hari 
dan dapat menjimatkan RM135 untuk rawatan wad kadar RM45 sehari. Dengan itu, 
sejumlah RM16,200 untuk bayaran masuk hospital dapat dielakkan oleh 120 orang 
pesakit ini. Sebagai kesimpulan, penggunaan Venofer untuk merawati anemia semasa 
dan selepas kehamilan sebagai pesakit luar adalah selamat, munasabah, menjimatkan 
dan mendapat pematuhan pesakit yang tinggi. 
 





A cross-sectional study was undertaken to evaluate if outpatient administration of in-
travenous iron sucrose complex (Venofer) was a sensible option in treating iron defi-
ciency anaemia during pregnancy and puerperium. A total of 120 patients with iron 
deficiency anaemia were recruited from the Obstetric Day Care Clinic at the Universiti 
Kebangsaan Malaysia Medical Centre (UKMMC) over 18 months from March 2003 to 
August 2004. The main outcome measures were haemoglobin increment, patients’ 
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compliance, adverse effects and saving from hospitalization fees. The pre-treatment 
haemoglobin (Hb) level was 8.5+0.85g/dl for the antenatal patient and 7.6+0.80 g/dl in 
the post-partum group. The mean post-treatment haemoglobin increment at day four-
teenth was 3.52+0.75g/dl. One patient developed skin rash while another had low-
grade pyrexia. Seven patients experienced mild metallic taste. There were no serious 
side effects or anaphylactic reactions. Ten patients (8.3%) did not complete their ther-
apy - eight delivered before completion of treatment; another two defaulted following 
delivery. The average number of Venofer used was seven ampoules i.e. 700mg per 
person, most of them required three sessions to complete the course. Outpatient 
treatment allows each patient to save hospitalization fees of RM45 per day, which to-
talled up to RM135 for a 3-days ward stay. An estimation of RM16,200 hospitalization 
fees for the 120 patients was avoided during the study period. In conclusion, outpatient 
treatment of anaemia in pregnancy and post-partum period using Venofer was safe 
and feasible, with high patient compliant and cost-savings from hospitalization fees.  
 






Pregnancy anaemia is defined by hae-
moglobin (Hb) of less than 110g/l in the 
first or third trimester or less than 105g/l 
in the second trimester. Iron deficiency 
with or without anaemia has many ad-
verse effects on the nervous system, in-
tellectual capacity, physical performance, 
immune response and pregnancy out-
come (Fairbanks & Beutler 1995, Baynes 
1994). The mother may be overwhelmed 
by easy fatigability, dyspnoea, headache, 
reduced exercise tolerance and weak-
ness. On the other hand, the fetus may 
encounter an increased risk of low birth 
weight and preterm delivery. 
Up to 30% of women in the post-partum 
period are affected by anaemia of under 
10g/dL and about 10% by severe anae-
mia of less than 8%. By far the main 
cause for this is the deficiency of iron 
supplied during pregnancy and blood 
loss during and after birth (Lebrecht et al. 
1995). Under normal circumstances, oral 
iron is the treatment of choice since it is 
simple, effective, safe and cheap. How-
ever, oral iron is better absorbed in an 
empty stomach but patient may experi-
ence side effects such as nausea, vom-
iting, gastritis, diarrhea and constipation. 
These side effects can be minimized by 
co-administration with food, although this 
may substantially decrease absorption, 
particularly of ferrous preparation 
(Perewusnyk et al. 2002). Even a patient 
who responds well to oral iron therapy 
would require a long time, usually months 
to reach the target haemoglobin level. 
This means that they have to suffer from 
iron deficiency for extended periods un-
necessarily (Al-Momen et al. 1996). 
A pregnant woman without anaemia 
may require at least 1000mg of elemental 
iron to be delivered to the haemopoietic 
organs while the anaemic patient may 
need more than 2600mg. This require-
ment cannot be met by the oral route in 
the majority of patients because of limited 
absorption, bio-availability and compli-
ance (Bynum et al. 1977, Lee & Feldman 
1993, Kahrilas & Hogan 1993). 
Parenteral iron therapy with intravenous 
iron-sucrose complex (Venofer) was first 
introduced to UKMMC in 2002.  It has 
been used to correct anaemia in preg-
nant women in whom the elemental iron 
requirement cannot be met by oral route. 
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Previous studies have shown that intra-
venous Venofer is safe and effective in 
pregnant and post-partum women with 
iron deficiency anaemia (Breymann et al. 




The aim of this study was to assess if 
administration of intravenous iron su-
crose complex (Venofer) was a sensible 
option in treating iron deficiency anaemia 
in pregnancy and puerperium using day-
care clinic in an urban hospital. A favor-
able outcome would imply its safe usage 
as an outpatient for treating anaemia in 




This was a cross-sectional observational 
study, recruiting all patients with iron de-
ficiency anaemia who were referred to 
the Obstetrics Day Care Unit, UKMMC 
for intravenous Venofer. The study was 
completed in 18 months from March 
2003 to August 2004. Baseline haemo-
globin (Hb) level was determined and 
reassessed in 14 days after treatment. 
Patients’ demography, number of visits to 
the Day Care Unit, total dosage, incre-
ment of haemoglobin level, adverse ef-
fect and their compliance to complete the 
full therapy were recorded. Patients with 
other causes of anaemia such as thalas-
semia trait, haemolytic anaemia, liver or 
renal disease were excluded.  
 
Calculation of Venofer dosage 
 
Total iron deficit (mg) = [Body weight (kg) x (target 
Hb–actual Hb)g/l x 0.24*] + depot iron (mg) 
 
For body weight of above 35 kg, the tar-
get Hb is 120 g/l and depot iron is 
500mg. 
     
*Factor = 0.0034 x 0.07 x 1000  
(iron content of Hb ~0.34%; Blood vol-
ume ~7% of body weight; factor 1000 is 
conversion from g to mg) 
 
Administration of Venofer 
 
The first 25mg of iron (i.e. 25mls of solu-
tion) was infused as a test dose over a 
period of 15 minutes. If there were no 
adverse events the remaining portion of 
the infusion was given. Infusion of 200mg 
iron sucrose in 200ml normal saline over 
1 hour 30 minutes was administered at 
an interval of 1 to 3 days to complete the 




A total of 120 patients were recruited. 
There were 70% Malay, 16% Chinese, 
10% Indian and 4% from other ethnic 
background. About half the patients 
(48%) were working mothers, 45% were 
housewives and 7% were students.  
The mean gestational age of those who 
were referred for anaemia in pregnancy 
was at 34.5 weeks. The pre-treatment Hb 
level was 8.5+0.85g/dl (7.2-8.9g/dl). In 
the post-partum group, the pre-treatment 
Hb was 7.6+0.80g/dl (7.2-8.8g/dl). Major-
ity of these patients (92%) had a history 
of either non-compliance or intolerable to 
oral iron supplement, hence were offered 
intravenous Venofer. The other 8% re-
quired rapid restoration due to recent 
blood lost from post-partum haemor-
rhage.  
Of those who completed treatment, the 
mean increment of Hb within 14 days 
was 3.52g/dl (2.9-4.6g/dl). Each patient 
received an average of seven ampoules 
i.e. 700mg of Venofer.   
Majority of the patients tolerated the 
treatment well with no discomfort or any 
significant complaint (Table 1). One pa-
tient developed skin rashes while on in-
fusion. She responded to intravenous 
Chlorpheniramine Maleate (Piriton) and 
the Venofer was completed at a slower 
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Table 1: Adverse effects of intravenous Venofer 
 
ADVERSE EFFECTS NUMBER 
Skin rash/Itching 1 
Fever < 38°C 1 
Metallic taste 7 
Nausea 15 
Anaphylactic reaction 0 
 
 
infusion rate. Another patient had low-
grade pyrexia of 38oC after receiving her 
second dose and the fever settled with 
Paracetamol. Seven patients complained 
of having a mild metallic taste and 15 
patients had nausea. There were no 
other undesirable effects such as head-
ache, dizziness, palpitations, dyspnoea, 
vomiting, abdominal pain, diarrhoea, 
muscle cramps, myalgia, shivering, chest 
pain, injection site pain, anaphylactic re-
action or hospitalization for further treat-
ment.  
Of the 120 patients who were recruited 
for the study, 10 patients (8.3%) did not 
complete their therapy - eight of them 
were antenatal mothers who delivered 
before completion of treatment; another 
two post-partum patients defaulted their 
follow-up.  
Venofer was approved as a formulary 
item and patients received free supply be 
it as an in or outpatient. However, the 
ward charge for an in-patient in UKMMC 
was RM45 per day. As most patients re-
quired at least a three-day infusion, it 
was estimated that each patient might 
save up to RM135. Our estimation was 
that during the study period on the 120 
outpatients, a total of RM 16,200 hospi-




Anaemia is a common deficit in preg-
nancy. Though traditionally it is treated 
by oral haematinics, some may require 
parenteral iron due to poor compliance to 
oral supplement, poor absorption or in-
tolerable gastro-intestinal side effects. 
Prior to year 2002, intra-muscular prepa-
ration iron dextran (Imferon) was the 
available parenteral preparation in 
UKMMC  However, iron dextran is to be 
discouraged because of its adverse ef-
fects including pain at injection site, ir-
regular absorption, staining of buttock 
and rarely, malignancy (Martini et al. 
1994, Roberson 1973).   
Parenteral iron using iron-sucrose com-
plex (Venofer) has largely replaced iron 
dextran. Numerous reports from Euro-
pean countries have proven its effective-
ness and patient tolerability (Al-Momen et 
al. 1996, Perewusnyk et al. 2002). The 
results of our observational study have 
shown that iron-sucrose complex is safe, 
is well tolerated and effective in treating 
anaemic pregnant and postpartum pa-
tients in a day care setting. There were 
120 patients in this study, twenty-four 
sustained minor adverse effects such as 
skin rash, low-grade pyrexia, metallic 
taste and nausea. There was no serious 
side effects or anaphylactic reactions 
reported.  
Iron-sucrose complex releases iron to 
the iron-binding proteins with a half-life of 
about 6 hours. This relatively short half-
life grants it effective and carries minimal 
risk of allergic reaction (Danielson 1998, 
Kraft et al. 2000, Rohling et al. 2000). 
Skin rash and fever can be prevented by 
giving a slow infusion over one to four 
hours or dividing the total dose into 
smaller portions (100-200mg/day). The 
side effects are mostly self-limited and 
resolve with symptomatic treatment.  
Unlike other parenteral iron prepara-
tions, iron-sucrose complex is taken up 
mainly by the reticuloendothelial system 
and not by the parenchymal cells of the 
liver, kidney, adrenal gland or other or-
gans. Therefore, organic toxicity such as 
pancreatic, myorcardial or hepatic he-
mosiderosis is less likely even with iron-
sucrose complex over-load (Macdougall 
et al. 1989). 
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Majority of the patients (92.8%) in this 
study completed the treatment course. 
The local urban population around 
UKMMC has proven themselves to be 
highly compliant to outpatient treatment, 
regardless of their background as 
housewives, working mothers or stu-
dents. Outpatient treatment allows less 
interruption to family or working life, is 
more convenient and cost saving. The 
avoidance of hospitalization could itself 
encourage patients’ compliance.  
Although iron-sucrose complex is ex-
pensive and the treatment requires intra-
venous infusion and is time consuming 
as compared to oral iron supplement, it is 
highly tolerated and rapidly effective. This 
study showed that the mean increment of 
Hb within 14 days was 3.52g/dl (2.9-
4.6g/dl). On the contrary, oral iron takes 
a longer time to achieve the target hae-
moglobin level and the increment rate is 
significantly slower (Al-Momen et al. 
1996). It is very important to correct an 
anaemic pregnant patient before delivery, 
as the maternal iron status will influence 
the newborn iron status as well. Infants of 
anaemic mothers are more likely to be-
come anaemic at 12 months of age, even 
when possible confounders such as 
socio-economic status, feeding practices 
and morbidity were taken into account 
(Colomer et al. 1990). In conclusion, out-
patient treatment of anaemia in preg-
nancy and post-partum period using 
Venofer is safe, feasible, with high pa-
tient compliance and saves cost from 
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